A prospective multicenter study to evaluate the impact of cryotherapy on dysphagia and quality of life in patients with inoperable esophageal cancer

Abstract

Background Dysphagia palliation in inoperable esophageal cancer continues to be a challenge. Self-expandable metal stents have been the mainstay of endoscopic palliation but have a significant risk of adverse events (AEs). Liquid nitrogen spray cryotherapy is an established modality that can be used with systemic therapy. This study reports the outcomes of cryotherapy, including dysphagia and quality of life (QoL), in patients receiving systemic therapy.

Methods This was a prospective multicenter cohort study of adults with inoperable esophageal cancer who underwent cryotherapy. QoL and dysphagia scores before and after cryotherapy were compared.

Results 55 patients received 175 cryotherapy procedures. After a mean of 3.2 cryotherapy sessions, mean QoL improved from 34.9 at baseline to 29.0 at last follow-up (P < 0.001) and mean dysphagia improved from 1.9 to 1.3 (P = 0.004). Patients receiving more intensive cryotherapy (≥ 2 treatments within 3 weeks) showed a significantly greater improvement in dysphagia compared with those not receiving intensive therapy (1.2 vs. 0.2 points; P = 0.003). Overall, 13 patients (23.6 %) received another intervention (1 botulinum toxin injection, 2 stent, 3 radiation, 7 dilation) for dysphagia palliation. Within the 30-day post-procedure period, there were three non-cryotherapy-related grade ≥ 3 AEs (all deaths). The median overall survival was 16.4 months.

Conclusion In patients with inoperable esophageal cancer receiving concurrent systemic therapy, adding liquid nitrogen spray cryotherapy was safe and associated with improvement in dysphagia and QoL without causing reflux. More intensive treatment showed a greater improvement in dysphagia and should be considered as the preferred approach.

Publikationsverlauf

Eingereicht: 18. Dezember 2022

Angenommen nach Revision: 25. Mai 2023

Accepted Manuscript online:
02. Juni 2023

Artikel online veröffentlicht:
25. Juli 2023

• References

• 1 Uhlenhopp DJ, Then EO, Sunkara T. et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol 2020; 13: 1010-1021
• 2 National Cancer Institute Surveillance Epidemiology, and End Results Program. Cancer stat facts: esophageal cancer. Available at (Accessed 06/06/2023): https://seer.cancer.gov/statfacts/html/esoph.html
• 3 Siegel RL, Miller KD, Fuchs HE. et al. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33
• 4 Karadag I, Karakaya S, Ates O. et al. CROSS or FLOT in distal esophageal and gastroesophageal cancer. J Coll Physicians Surg Pak 2021; 31: 326-329
• 5 Depypere L, Thomas M, Moons J. et al. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy. World J Surg Oncol 2019; 17: 89
• 6 NCCN Guidelines. Available at (Accessed 06/13/2023): https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433
• 7 Ilson DH, Forastiere A, Arquette M. et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316-323
• 8 Bakheet N, Park JH, Hu HT. et al. Fully covered self-expandable esophageal metallic stents in patients with inoperable malignant disease who survived for more than 6 months after stent placement. Br J Radiol 2019; 92: 20190321
• 9 Medeiros VS, Martins BC, Lenz L. et al. Adverse events of self-expandable esophageal metallic stents in patients with long-term survival from advanced malignant disease. Gastrointest Endosc 2017; 86: 299-306
• 10 Diamantis G, Scarpa M, Bocus P. et al. Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia. World J Gastroenterol 2011; 17: 144-150
• 11 Barthel JS, Kucera S, Harris C. et al. Cryoablation of persistent Barrett’s epithelium after definitive chemoradiation therapy for esophageal adenocarcinoma. Gastrointest Endosc 2011; 74: 51-57
• 12 Kachaamy T, Prakash R, Kundranda M. et al. Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer. Gastrointest Endosc 2018; 88: 447-455
• 13 Shah T, Kushnir V, Mutha P. et al. Neoadjuvant cryotherapy improves dysphagia and may impact remission rates in advanced esophageal cancer. Endosc Int Open 2019; 7: E1522-e1527
• 14 Eluri S, Kaul V, Sharma NR. et al. Palliative endoscopic spray cryotherapy to prevent worsening of dysphagia and improve quality of life in esophageal cancer. J Clin Oncol 2021; 39: 219
• 15 Hanada Y, Leggett CL, Iyer PG. et al. Spray cryotherapy prevents need for palliative stenting in patients with esophageal cancer-associated dysphagia. Dis Esophagus 2022; 35: doab051
• 16 Blazeby JM, Conroy T, Hammerlid E. et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003; 39: 1384-1394
• 17 Mellow MH, Pinkas H. Endoscopic therapy for esophageal carcinoma with Nd:YAG laser: prospective evaluation of efficacy, complications, and survival. Gastrointest Endosc 1984; 30: 334-339
• 18 Ogilvie AL, Dronfield MW, Ferguson R. et al. Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut 1982; 23: 1060-1067
• 19 U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.03, June 14 2010. Available at (Accessed 19/06/2023): https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
• 20 Peters TJ. Multifarious terminology: multivariable or multivariate? Univariable or univariate? . Paediatr Perinat Epidemiol 2008; 22: 506
• 21 Hintze J. PASS 11. Kaysville, Utah, USA: NCSS, LLC; 2011. www.ncss.com
• 22 Dai Y, Li C, Xie Y. et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev 2014; 10: CD005048
• 23 Janmaat VT, Steyerberg EW, van der Gaast A. et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev 2017; 11: CD004063
• 24 Santero M, Pérez-Bracchiglione J, Acosta-Dighero R. et al. Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews. BMC Cancer 2021; 21: 712
• 25 van Kleef JJ, Ter Veer E, van den Boorn HG. et al. Quality of life during palliative systemic therapy for esophagogastric cancer: systematic review and meta-analysis. J Natl Cancer Inst 2020; 112: 12-29
• 26 Mulder FI, Hovenkamp A, van Laarhoven HWM. et al. Thromboembolic and bleeding complications in patients with oesophageal cancer. Br J Surg 2020; 107: 1324-1333
• 27 Ikeda E, Kojima T, Kaneko K. et al. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 2011; 41: 964-972
• 28 Zhan PL, Canavan ME, Ermer T. et al. Utilization and outcomes of radiation in stage IV esophageal cancer. JTO Clin Res Rep 2022; 3: 100429
• 29 Penniment MG, De Ieso PB, Harvey JA. et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol 2018; 3: 114-124
• 30 Cocks K, King MT, Velikova G. et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 2012; 48: 1713-1721
• 31 Sigounas DE, Krystallis C, Couper G. et al. Argon plasma coagulation compared with stent placement in the palliative treatment of inoperable oesophageal cancer. United European Gastroenterol J 2017; 5: 21-31
• 32 Chen J, Qian W, Mu F. et al. The future of cryoablation: an abscopal effect. Cryobiology 2020; 97: 1-4